[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pharmacology](https://durgical.com/en/pharmacology/) › [Erythropoiesis-stimulating agents (ESAs)](https://durgical.com/en/pharmacology/classes/erythropoiesis-stimulating-agents/) › Luspatercept

# Luspatercept

## ESAs?

Erythropoiesis-stimulating agents (ESAs)

## Pregnancy: contraindicated?

It may harm the fetus: a pregnancy test is done before starting, contraception is used during treatment and for at least 3 months after, and breastfeeding is avoided for 3 months.

A ligand trap that lets red-cell precursors mature, reducing transfusion needs in beta thalassaemia and some myelodysplastic syndromes.

Updated Nov 1, 2026

Also called: luspatercept-aamt

## Quick facts

**Group**
[Erythropoiesis-stimulating agents (ESAs)](https://durgical.com/en/pharmacology/classes/erythropoiesis-stimulating-agents/)

**Target**
TGF-β superfamily ligands that brake red-cell maturation (GDF11, GDF8, activin B)

**Used for**
Anaemia in adults

**Key effects**
Bone · Headache · Flu-like symptoms

**Monitor**
Haemoglobin before each dose · Signs of thrombosis

**ATC**
B03XA06

No doses: the clinician sets them by the current guideline.

On this page

- The basics Mechanism of action
- Indications
- Adverse effects
- Pharmacokinetics
- Memory aid

- Clinical What the labels mean

- Safety Contraindications
- Key interactions
- What is monitored
- Administration and safety
- Pregnancy and breastfeeding
- Nursing care

- Study Test yourself

- Connections Connections

## Mechanism of action

◆**TGF-β superfamily ligands that brake red-cell maturation (GDF11, GDF8, activin B)**Luspatercept

ⓘ No structure with luspatercept is available; the figure shows human GDF11 held by the extracellular domain of activin receptor type 2B (from rat) and ALK5. Luspatercept is built from a modified human version of that receptor domain.

**Target in 3D:** TGF-β superfamily ligands that brake red-cell maturation (GDF11, GDF8, activin B). PDB structure 6MAC (RCSB PDB, public domain). [View the structure at RCSB PDB](https://www.rcsb.org/structure/6MAC) · Drag to rotate · pinch to zoom

Luspatercept is a fusion protein: a modified extracellular domain of activin receptor type 2B joined to the Fc part of human IgG1. It traps GDF11, GDF8 and activin B, which reduces SMAD2/3 signalling in late erythroid precursors. Freed from that brake, the cells mature into red cells. It acts on a different step from erythropoietin.

- TGF-β family ligands brake late red-cell maturation
- Luspatercept traps these ligands in the blood
- SMAD2/3 signalling in erythroblasts falls
- More precursors mature; fewer transfusions are needed

## Indications

- Anaemia in adults with transfusion-dependent beta thalassaemia [Thalassemias (α and β) →](https://durgical.com/en/conditions/thalassemias/)
- Anaemia in lower-risk myelodysplastic syndromes needing transfusion, after or instead of erythropoiesis-stimulating agents [Myelodysplastic syndromes →](https://durgical.com/en/conditions/myelodysplastic-syndromes/)

## Adverse effects

### Common

- Bone, joint or muscle pain
- Headache, dizziness, tiredness
- Flu-like symptoms, cough
- Diarrhoea, nausea, abdominal pain
- Injection-site pain, redness or itching

### Serious (rare, important)

- Thromboembolism (leg swelling, chest pain, breathlessness, stroke signs), mainly in thalassaemia patients after splenectomy with other risk factors
- High blood pressure
- Extramedullary haematopoietic masses (back pain, weakness, loss of bladder or bowel control)

## Contraindications

- Hypersensitivity to luspatercept
- Caution: previous clots, splenectomy, hypertension, smoking, extramedullary haematopoietic masses
- Pregnancy (may harm the fetus)

## Key interactions

**Oestrogen-containing hormone therapy or contraceptives**
Add to the clot risk; reviewed before starting

## What is monitored

- Haemoglobin before each dose
- Blood pressure regularly
- Transfusion needs to judge response
- Signs of thrombosis

## Administration and safety

- Subcutaneous injection by a health professional in a clinic
- The dose may be delayed, changed or stopped according to haemoglobin and side effects
- A missed appointment is rescheduled at once

## Pregnancy and breastfeeding

It may harm the fetus: a pregnancy test is done before starting, contraception is used during treatment and for at least 3 months after, and breastfeeding is avoided for 3 months.

## Nursing care

- Check haemoglobin and blood pressure before each injection
- Ask about leg swelling, chest pain or neurological symptoms
- Teach contraception during treatment and for at least 3 months after
- Ask about splenectomy and smoking

## Pharmacokinetics

**Absorption**
Subcutaneous injection every few weeks

## Memory aid

«LUSPA-trap»: it traps the ligands that brake the red cells, so they can mature.

## Test yourself

Think of the answer, then tap the question to see it.

## How does luspatercept differ from epoetin?

It traps TGF-β family ligands to allow late red-cell maturation, instead of stimulating the erythropoietin receptor.

## In which thalassaemia patients is thrombosis most likely?

Those who have had a splenectomy and have other risk factors.

## Which two diseases is it used in?

Transfusion-dependent beta thalassaemia and lower-risk myelodysplastic syndromes.

[Add to my cards (3)](https://durgical.app/estudiar/?add=/en/pharmacology/luspatercept/)

[More Pharmacology questions →](https://durgical.com/en/practice/?f=pharmacology)

## What the labels mean

**Pregnancy: contraindicated**
It may harm the fetus: a pregnancy test is done before starting, contraception is used during treatment and for at least 3 months after, and breastfeeding is avoided for 3 months.

## Connections

## Related drugs 2

- [Epoetin alfa](https://durgical.com/en/pharmacology/epoetin-alfa/)
- [Darbepoetin alfa](https://durgical.com/en/pharmacology/darbepoetin-alfa/)

## Related conditions 2

- [Thalassemias (α and β)](https://durgical.com/en/conditions/thalassemias/)
- [Myelodysplastic syndromes](https://durgical.com/en/conditions/myelodysplastic-syndromes/)

[← Back to the class: Erythropoiesis-stimulating agents (ESAs)](https://durgical.com/en/pharmacology/classes/erythropoiesis-stimulating-agents/)

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: [Luspatercept-aamt Injection: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a620043.html) (MedlinePlus (U.S. National Library of Medicine), 2025); [ATCDDD - ATC/DDD Index](https://atcddd.fhi.no/atc_ddd_index/?code=B03XA&showdescription=no) (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/pharmacology/luspatercept/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pharmacology/luspatercept/